Quality & complianceOfficial

Octostim nasal spray supply problems in Denmark linked to quality issues, DKMA says

🇩🇰 DKMA · Tue 10 Nov 2026

The Danish Medicines Agency reports ongoing supply difficulties for Ferring's desmopressin nasal spray Octostim 1.5 mg/ml, with a stated expected period running to early February 2027.

The Danish Medicines Agency (DKMA) has updated its notice on supply difficulties for Octostim 1.5 mg/ml nasal spray, marketed in Denmark by Ferring Lægemidler A/S. The page was first published on 5 May 2022 and was last updated on 10 November 2026.

The active substance is desmopressin (ATC code H01BA02). DKMA gives quality problems as the cause of the supply disruption.

The agency lists the expected period of the difficulties as July 2020 to the start of February 2027. The notice does not explain the quality issue, say how much stock is available, or describe any measures the company has taken.

DKMA directs questions about the current status to the company, Ferring Lægemidler A/S. The notice sits within the agency's wider announcements on medicine supply, where it publishes information on shortages.

What it means for your team

  • Pharmacovigilance and supply-chain teams should note that the stated expected duration of the Octostim disruption extends to early February 2027.
  • The notice gives no detail on the quality problem or on stock levels, so teams needing current availability should contact Ferring Lægemidler A/S directly, as DKMA advises.
  • Market-access and medical teams in Denmark may wish to monitor DKMA's supply notices for changes to the expected period.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →